The study and its comparison
Twenty long-term low-dose aspirin users with capsule-endoscopy evidence of small-bowel injury were randomized to polaprezinc or no polaprezinc for four weeks. Repeat capsule examinations counted reddened areas and erosions or ulcers. [1]
Lesion counts decreased significantly within the treated group but not within controls. The retrieved abstract does not supply a clear between-group treatment-effect estimate, despite describing comparisons between groups. [1]
What the finding establishes
Significance in one group and not the other is not itself a significant treatment difference. The very small sample and lack of a matched placebo add uncertainty. Funding and conflicts were not established from the abstract. This study addresses small-bowel lesions, not gastritis, and does not justify copying its compound amount as an elemental-zinc dose. [1]
A hypothetical distinction
Imagine one group has P below 0.05 and the other does not. A direct comparison is still needed to establish their difference.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.